Preclinical safety and efficacy of andexanet alfa in animal models
Author:
Affiliation:
1. Portola Pharmaceuticals Inc.; South San Francisco CA USA
Funder
Bayer HealthCare Pharmaceuticals
Janssen Scientific Affairs, LLC
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.13768/fullpdf
Reference19 articles.
1. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association;Camm;Eur Heart J,2012
2. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society;January;J Am Coll Cardiol,2014
3. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines;Guyatt;Chest,2012
4. Prevention and treatment of venous thromboembolism-International Consensus Statement;Nicolaides;Int Angiol,2013
5. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism;Konstantinides;Eur Heart J,2014
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Grundlagen zur Anwendung von Andexanet;Hämostaseologie;2023-10-09
2. Cerebral infarction following administration of andexanet alfa for anticoagulant reversal in a patient with traumatic acute subdural hematoma;Surgical Neurology International;2023-08-11
3. Andexanet alfa (ONDEXXYA<sup>®</sup> for Intravenous Injection 200 mg), a reversal agent for direct factor Xa inhibitors: pharmacological characteristics and clinical evidence;Folia Pharmacologica Japonica;2023
4. A Historical Perspective on the Reversal of Anticoagulants;Seminars in Thrombosis and Hemostasis;2022-09-02
5. Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies;Seminars in Thrombosis and Hemostasis;2020-07-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3